This project will develop tools to predict who is most likely to benefit from rapid-acting mental health treatments, who may be at risk for side effects or relapse, and when symptoms may be worsening before they are obvious. The project examines multiple treatments (e.g., psilocybin, MDMA, ketamine, neuromodulation) for PTSD and depression across multiple clinical trials and real-world care settings. By combining clinical, digital, genetic, wearable, and remote biological data, the aim is to create practical measures for tracking outcomes and more personalized care over time. Data collected under this award will be deidentified and housed in the ARPA-H EVIDENT Data Repository.